

PART - I

BLISS GVS PHARMA LIMITED
 Regd Office: 102, Hyde Park, Sakinaka Road,
 Andheri (East), Mumbai - 400 072
AUDITED FINANCIAL RESULTS
 FOR THE QUARTER / YEAR ENDED 31.03.2012

SR. NO.	PARTICULARS	STANDALONE				CONSOLIDATED	
		31.03.2012 (UNAUDITED)	31.12.2011 (UNAUDITED)	31.03.2011 (UNAUDITED)	31.03.2012 (AUDITED)	31.03.2011 (AUDITED)	31.03.2012 (AUDITED)
1	INCOME FROM OPERATIONS						
	(a) NET SALES (NET OF EXCISE DUTY)	7071.52	6312.78	5928.25	26442.53	21795.57	26442.53
	(b) OTHER OPERATING INCOME	67.92	60.44	88.23	224.96	88.24	224.96
	TOTAL INCOME FROM OPERATIONS (NET)	7139.44	6373.22	6016.48	26667.49	21883.81	26667.49
2	EXPENSES						
	a) CONSUMPTION OF RAW MATERIALS	4262.77	3623.71	4284.71	14799.48	12027.84	14799.48
	b) PURCHASE OF TRADED GOODS	217.62	674.95	2.73	1001.29	781.00	1001.29
	c) (INCREASE)/DECREASE IN STOCK IN TRADE	-40.36	-101.21	176.74	-53.60	-69.41	-53.60
	d) EMPLOYEE BENEFIT EXPENSES	182.59	148.12	104.19	603.15	430.47	612.68
	e) DEPRECIATION / AMORTISATION	65.53	0.75	106.70	364.61	546.95	364.61
	f) OTHER EXPENDITURE	948.62	900.69	896.02	3198.95	2841.35	3207.39
	TOTAL EXPENSES	5636.77	5247.00	5570.09	18913.88	16558.20	18913.85
3	PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COST & EXCEPTIONAL ITEMS (1-2)	1502.68	1126.21	446.39	6753.61	5325.61	6735.65
4	OTHER INCOME	431.45	577.55	92.35	1620.05	187.27	1608.34
5	PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COST (3+4)	1934.13	1703.77	538.74	8373.66	5512.88	8344.99
6	FINANCE COST	126.34	96.69	68.44	402.41	214.74	403.05
7	PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5-6)	1807.79	1607.08	470.30	7971.25	5298.14	7941.93
8	EXCEPTIONAL ITEMS						
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	1041.11	721.70	704.05	2698.35	1235.11	2698.35
12	MINORITY INTEREST						
14	PAID - UP EQUITY CAPITAL	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)				20011.63	15630.62	20034.62

(Rs. in Lakhs)

PART - II

PARTICULARS	STANDALONE				CONSOLIDATED
	31.03.2012 (UNAUDITED)	31.12.2011 (UNAUDITED)	31.03.2011 (UNAUDITED)	31.03.2012 (AUDITED)	
A PARTICULARS OF SHAREHOLDING					
1 AGGREGATE OF NON-PROMOTER SHAREHOLDING - NO. OF SHARES (FACE VALUE RS. 1/- EACH) - PERCENTAGE OF SHAREHOLDING (%)	36187842 35.08	36187842 35.08	37300583 36.16	36187842 35.08	36187842 35.08
2 PROMOTER AND PROMOTER GROUP SHAREHOLDING					
A) PLEDGE/ENCUMBERED - NO. OF SHARES (FACE VALUE RE. 1/- EACH) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE CAPITAL OF THE COMPANY)	- - -	- - -	- - -	- - -	- - -
B) NON - ENCUMBERED - NO. OF SHARES (FACE VALUE RE. 1/- EACH) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE CAPITAL OF THE COMPANY)	66958830 100.00 64.92	66958830 100.00 64.92	65846089 100.00 63.84	66958830 100.00 64.92	66958830 100.00 64.92

Particulars	Quarter ended 31 March 2012
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	5
Disposed off during the quarter	5
REMAINING UNSOLVED AT THE END OF THE QUARTER	-

Particulars	STANDALONE			CONSOLIDATED
	Mar-12	Mar-11	Mar-12	
I. EQUITY AND LIABILITIES				
1 SHAREHOLDERS' FUNDS :				
(i) Share Capital	1,031.47	1,031.47	1,031.47	
(ii) Reserves and Surplus	20,011.63	15,630.62	20,034.62	
(iii) Money received against share warrants				
Sub-total - Shareholders' funds	21,043.10	16,662.09	21,066.08	
2 Share Application money pending allotment				
3 Non-Current liabilities				
(i) Long term Borrowings	294.19	365.25	3,762.93	
(ii) Deferred tax liabilities (Net)	120.17	-	120.17	
(iii) Other long term liabilities				
(iv) Long term provisions	51.36	58.06	51.36	
Sub-total - Non-current liabilities	465.72	423.32	3,934.46	
4 Current liabilities				
(i) Short term Borrowings	222.11	328.69	590.47	
(ii) Trade payables	4,011.69	3,139.73	4,015.13	
(iii) Other current liabilities	533.20	434.66	610.19	
(iv) Short term provisions	758.35	361.26	758.35	
Sub-total -current liabilities	5,525.35	4,264.33	5,974.14	
Total	27,034.17	21,349.74	30,974.68	
II. ASSETS				
1 Non-current assets				
(a) Fixed Assets	4,065.91	2,748.27	4,693.58	
(b) Non-current investments	860.71	0.01	0.01	
(c) Deferred tax assets		37.44		
(d) Long term loans and advances	968.43	2,908.58	5,137.22	
(e) Other non current assets				
Sub-total - Non-current assets	5,895.04	5,694.30	9,830.82	
2 Current assets				
(a) Current investments	80.26	-	80.26	
(b) Inventories	1,268.09	1,161.13	1,268.09	
(c) Trade receivables	12,859.02	11,961.23	12,859.02	
(d) Cash and Bank balances	5,790.40	1,798.30	5,800.56	
(e) Short term loans and advances	972.30	704.09	977.59	
(f) Other current assets	169.06	30.69	158.34	
Sub-total - Current assets	21,139.13	15,655.44	21,143.86	
Sub-total - Current assets	27,034.17	21,349.74	30,974.68	

PBT UP
BY
26.73
Cr.

PAT UP
BY
12.20
Cr.

ETS
RS.5.12

NOTES:-

1. THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.
2. THE CONSOLIDATED RESULTS INCLUDES THE AUDITED FINANCIAL RESULTS OF PARENT COMPANY, THE SUBSIDIARIES NAMELY BLISS GVS INTERNATIONAL PTE LTD (100% HOLDING) AND BLISS INDASI LIFE SCIENCES PVT LTD (51% HOLDING). THESE COMPANIES BECAME SUBSIDIARIES IN THE CURRENT FINANCIAL YEAR AND HENCE CONSOLIDATED FINANCIAL STATEMENTS ARE APPLICABLE FROM THE CURRENT YEAR ONWARDS. ACCORDINGLY, PREVIOUS FIGURES ARE NOT GIVEN.
3. TAX EXPENSES FOR THE QUARTER ENDED AND YEAR ENDED 31ST MARCH 2012 INCLUDES SHORT PROVISION OF EARLIER YEARS OF RS. 245 LACS.
4. THE BOARD HAS RECOMMENDED A DIVIDEND OF 40% I.e Rs. 0.40 PER EQUITY SHARE FOR THE YEAR ENDED 31ST MARCH 2012.
5. THE FIGURES FOR THE QUARTER ENDED MARCH 31, 2012 ARE THE BALANCING FIGURES BETWEEN THE AUDITED FIGURES IN RESPECT OF THE FULL FINANCIAL YEAR ENDED MARCH 31, 2012 AND THE PUBLISHED YEAR TO DATE FIGURES UP TO THE THIRD QUARTER ENDED DECEMBER 31, 2011 WHICH HAVE BEEN REGROUPED / REARRANGED, WHEREVER NECESSARY, TO CONFORM TO FORMATS PRESCRIBED BY SEBI VIDE ITS CIRCULAR DATED APRIL 16, 2012 IN LINE WITH REVISED SCHEDULE VI. FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED WHEREVER NECESSARY.
6. THE ABOVE RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON MAY 30TH MAY 2012

FOR BLISS GVS PHARMA LIMITED

PLACE : MUMBAI

DATE : 30TH MAY 2012

**S.D./
S.N.KAMATH
MANAGING DIRECTOR**